Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer
Cancer subtypes may have distinct metabolic vulnerabilities that can be exploited for therapeutic interventions. Here, the authors show that in lung cancer, genetic activation of distinct oncogenic receptor tyrosine kinases results in unique metabolic liabilities and, in particular, EGFR aberrant ca...
Guardado en:
Autores principales: | Nan Jin, Aiwei Bi, Xiaojing Lan, Jun Xu, Xiaomin Wang, Yingluo Liu, Ting Wang, Shuai Tang, Hanlin Zeng, Ziqi Chen, Minjia Tan, Jing Ai, Hua Xie, Tao Zhang, Dandan Liu, Ruimin Huang, Yue Song, Elaine Lai-Han Leung, Xiaojun Yao, Jian Ding, Meiyu Geng, Shu-Hai Lin, Min Huang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9657645615f24b61be1f24096a3bc13c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies
por: Mengfei Cheng, et al.
Publicado: (2021) -
Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: C. I. Edvard Smith, et al.
Publicado: (2021) -
Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Sachin Gupta, et al.
Publicado: (2008) -
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
por: Mohamed A. Ismail, et al.
Publicado: (2021) -
NEAP/DUSP26 suppresses receptor tyrosine kinases and regulates neuronal development in zebrafish
por: Chi-Hwa Yang, et al.
Publicado: (2017)